Figure 1. Kaplan-Meier overall survival (OS) curves in patients with KRAS+/TP53+ mutant colorectal cancer who received therapy in a phase I clinical trial, stratified by KRAS G13 mutation status (due to sample size, all p values are unadjusted).
.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.